WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 5 fonti

This triple-action jab can lower your blood sugar and weight

A new triple-action weekly injection, retatrutide, has demonstrated significant reductions in blood sugar and body weight during phase 3 clinical trials.

Raccontata da

theguardian.com

medpagetoday.com

newsbytesapp.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

newsbytesapp.comStai leggendo18 h fa

This triple-action jab can lower your blood sugar and weight

A new triple-action weekly injection, retatrutide, has demonstrated significant reductions in blood sugar and body weight during phase 3 clinical trials.

Timeline cronologica

sabato 6 giugno 2026·healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
domenica 7 giugno 2026·theguardian.com
Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests needed

theguardian.com

1 g fa

Weekly diabetes jab shown to reduce blood-sugar levels and body weight

Retatrutide, Eli Lilly's weekly injection, reduced HbA1c 1.7-1.9 points and weight 11.5-15.3% in 930 diabetics—4× better than placebo. For health IT leaders, this signals a market shift toward multi-target biologics, reshaping pharma partnerships and healthcare data infrastructure investments.

Leggi questa versione → originale

gulfnews.com1 g fa

New weekly diabetes jab cuts blood sugar, body weight in major trial

New weekly diabetes jab retatrutide cuts blood sugar and drives double-digit weight loss in type 2 diabetes patients in major phase 3 trial, The Lancet reports.

Leggi questa versione → originale

medpagetoday.com1 g fa

Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

But its key advantage is in its weight reduction abilities

Leggi questa versione → originale

healio.com3 g fa

Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’

NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options, according to data from two phase 3…

Leggi questa versione → originale

domenica 7 giugno 2026·

gulfnews.com

New weekly diabetes jab cuts blood sugar, body weight in major trial

New weekly diabetes jab retatrutide cuts blood sugar and drives double-digit weight loss in type 2 diabetes patients in major phase 3 trial, The Lancet reports.

domenica 7 giugno 2026·

medpagetoday.com

Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

But its key advantage is in its weight reduction abilities

lunedì 8 giugno 2026·

newsbytesapp.com

This triple-action jab can lower your blood sugar and weight

A new triple-action weekly injection, retatrutide, has demonstrated significant reductions in blood sugar and body weight during phase 3 clinical trials.